Humanwell pharmaceutical's new class 1.1 drug, propofol sodium, was approved again

Propofol sodium is used for intravenous induction during general anesthesia, which is the prodrug of propofol and has stronger sedative effect Insight database shows that humanwell pharmaceutical has obtained the clinical approval for the second time, and the current clinical trial progress of the drug is phase II The original manufacturer of propofol sodium is Japanese Weicai, but humanwell Pharmaceutical Co., Ltd applied for clinical application in June 2008 before the product was launched, so the drug is 1.1 class It was not until the end of 2008 that the original research products of Weicai were listed in the United States, but they stopped selling four years after they were listed The specific reason is unknown In 2010, Weicai filed a clinical application (jxhl1000244) in China, but in 2011, it voluntarily revoked the application However, Sichuan hisic, Liaoning hisic and Shaanxi synthetic pharmaceutical industry declared propofol sodium and its dihydrate according to category 3.1 in the second year after the withdrawal of Weicai's declaration Propofol sodium for injection, developed jointly by Yichang humanwell and West China Hospital of Sichuan University, is a water-soluble propofol prodrug, and also the most advanced short-term general intravenous anesthetic researched abroad, with quick onset and recovery The product developed by Eisai company in the United States has been approved by FDA for listing on December 12, 2008, and the trade name is luse2 dra Humanwell said that after successful research and development, it will fill the gap in the clinical use of the drug in China and gradually narrow the gap in drug use between China and the United States and other developed countries Humanwell pharmaceutical is a leading enterprise in the field of narcotic drugs in China, with the market share of narcotic drugs ranking first in China The research and development of this product will enrich the company's product line, and further consolidate the company's dominant position in the field of narcotic analgesia.